Kotecha Rupesh, La Rosa Alonso, Brown Paul D, Vogelbaum Michael A, Navarria Pierina, Bodensohn Raphael, Niyazi Maximilian, Karschnia Philipp, Minniti Giuseppe
Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, USA.
Department of Radiation Oncology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA.
Neuro Oncol. 2025 Mar 7;27(3):597-615. doi: 10.1093/neuonc/noae220.
As cancer patients with intracranial metastatic disease experience increasingly prolonged survival, the diagnosis and management of recurrent brain metastasis pose significant challenges in clinical practice. Prior to deciding upon a management strategy, it is necessary to ascertain whether patients have recurrent/progressive disease vs adverse radiation effect, classify the recurrence as local or distant in the brain, evaluate the extent of intracranial disease (size, number and location of lesions, and brain metastasis velocity), the status of extracranial disease, and enumerate the interval from the last intracranially directed intervention to disease recurrence. A spectrum of salvage local treatment options includes surgery (resection and laser interstitial thermal therapy [LITT]) with or without adjuvant radiotherapy in the forms of external beam radiotherapy, intraoperative radiotherapy, or brachytherapy. Nonoperative salvage local treatments also range from single fraction and fractionated stereotactic radiosurgery (SRS/FSRS) to whole brain radiation therapy (WBRT). Optimal integration of systemic therapies, preferably with central nervous system (CNS) activity, may also require reinterrogation of brain metastasis tissue to identify actionable molecular alterations specific to intracranial progressive disease. Ultimately, the selection of the appropriate management approach necessitates a sophisticated understanding of patient, tumor, and prior treatment-related factors and is often multimodal; hence, interdisciplinary evaluation for such patients is indispensable.
随着颅内转移性疾病的癌症患者生存期越来越长,复发性脑转移瘤的诊断和治疗在临床实践中带来了重大挑战。在决定治疗策略之前,有必要确定患者是患有复发性/进展性疾病还是放射性不良反应,将复发分类为脑内局部复发或远处复发,评估颅内疾病的范围(病变的大小、数量和位置以及脑转移速度)、颅外疾病的状况,并计算从上一次颅内定向干预到疾病复发的时间间隔。一系列挽救性局部治疗方案包括手术(切除和激光间质热疗[LITT]),可联合或不联合以体外放射治疗、术中放射治疗或近距离放射治疗形式的辅助放疗。非手术挽救性局部治疗也包括单次分割和分次立体定向放射外科治疗(SRS/FSRS)到全脑放射治疗(WBRT)。全身治疗的最佳整合,最好具有中枢神经系统(CNS)活性,可能还需要重新检查脑转移瘤组织,以确定颅内进展性疾病特有的可操作分子改变。最终,选择合适的治疗方法需要对患者、肿瘤和既往治疗相关因素有深入的了解,并且通常是多模式的;因此,对此类患者进行多学科评估是必不可少的。